{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"7.550","floor":"6.550"},"ipodate":{"start":"2019-10-29 00:00:00","end":"2019-11-01 00:00:00"},"minimumcapital":"3050.43","subscribed":"12.95","marketcap":"37.34億","H_marketcap":"--","pe":"--","codesrate":"15.00","link":"https://staticpdf.iqdii.com/stockdata/notice/01875/2019/2019102900010_c.pdf","ipopricing":"6.550","resultdate":"2019-11-07 00:00:00","enddate":"2019-11-01 00:00:00","listeddate":"2019-11-08 00:00:00","issuenumber":"9000.00萬","issuenumberhK":"900.00萬","issuenumberother":"8100.00萬","grayprice":"6.13","sponsors":"工銀國際融資有限公司","raisemoney":"51140.00萬","use":"1、約30.0%（或153.5百萬港元）將為TAB008的進行中及計劃進行的臨床試驗、注冊備案準備及潛在商業推出（包括銷售及營銷）提供資金；\n2、約50.0%（或255.7百萬港元）將為我們研發中的其他在研藥物的進行中及計劃進行的臨床前及臨床試驗、設施擴充、注冊備案準備及潛在商業推出（包括銷售及營銷）提供資金；\n3、約15.0%，或76.7百萬港元將用于非項目指定的資本開支；\n4、約2.0%（或10.2百萬港元）將為透過內部研究及外部許可以及業務開發合作，持續擴展癌癥及其他潛在治療領域的產品組合提供資金；\n5、約3.0%（或15.3百萬港元）將用于我們的營運資金及其他一般企業用途。","shares":400,"leadagent":"工銀國際證券有限公司,元大證券(香港)有限公司,華興證券(香港)有限公司,中國光大證券(香港)有限公司,六福證券(香港)有限公司,聯合證券有限公司","bookrunners":"工銀國際融資有限公司,元大證券(香港)有限公司,華興證券(香港)有限公司,中國光大證券(香港)有限公司","coordinator":"工銀國際融資有限公司,元大證券(香港)有限公司","firstDayOpen":"6.43","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"工銀國際證券有限公司","code":"E01875","name":"東曜藥業－Ｂ","fullname":"東曜藥業股份有限公司"},"institutioninfo":{"principaloffice":"中國蘇州市蘇州工業園區長陽街120號","registrars":"卓佳證券登記有限公司","registrarstel":"(852) 2980 1333 ","chairman":"付山","secretary":"姚朝昶,呂穎一","telephone":"(86512) 6790 1858","substantialshareholders":"晟德大藥廠(31.43%),Vivo Capital(17.97%),鈞信(9.93%),Advantech Capital V(8.62%)","principalactivities":"公司是一間臨床階段生物制藥公司，致力于開發及商業化創新型腫瘤藥物及療法。","website":"http://www.totbiopharm.com.cn"},"managerinfo":[{"managername":"付山","post":"董事會主席兼非執行董事","rankno":1},{"managername":"黃純瑩","post":"執行董事兼總經理","rankno":2},{"managername":"劉軍","post":"執行董事、首席科學官兼副總經理","rankno":3}],"investorinfo":[{"institutionname":"Vivo Funds","shareholding":"11,964,400.0","percentage":13.29,"ReleaseDate":"2020-05-08 00:00:00","relatedparty":"Vivo Capital LLC","subsidiary":["Vivo Funds"],"InverstorType":"基金"},{"institutionname":"年興國際(維京群島)有限公司","shareholding":"5,982,000.0","percentage":6.65,"ReleaseDate":"2020-05-08 00:00:00","relatedparty":"年興紡織股份有限公司","subsidiary":["年興國際(維京群島)有限公司"],"InverstorType":"公司"},{"institutionname":"晟德大藥廠股份有限公司","shareholding":"5,982,000.0","percentage":6.65,"ReleaseDate":"2020-05-08 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"}],"TotalShareholdingPercentage":26.59},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":518}